AU2006323992B2 - Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis - Google Patents

Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis Download PDF

Info

Publication number
AU2006323992B2
AU2006323992B2 AU2006323992A AU2006323992A AU2006323992B2 AU 2006323992 B2 AU2006323992 B2 AU 2006323992B2 AU 2006323992 A AU2006323992 A AU 2006323992A AU 2006323992 A AU2006323992 A AU 2006323992A AU 2006323992 B2 AU2006323992 B2 AU 2006323992B2
Authority
AU
Australia
Prior art keywords
lower alkyl
substituted
mono
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006323992A
Other languages
English (en)
Other versions
AU2006323992A1 (en
Inventor
Paul W. Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006323992A1 publication Critical patent/AU2006323992A1/en
Application granted granted Critical
Publication of AU2006323992B2 publication Critical patent/AU2006323992B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006323992A 2005-12-06 2006-12-05 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis Ceased AU2006323992B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74278105P 2005-12-06 2005-12-06
US60/742,781 2005-12-06
PCT/EP2006/069335 WO2007065898A1 (en) 2005-12-06 2006-12-05 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis

Publications (2)

Publication Number Publication Date
AU2006323992A1 AU2006323992A1 (en) 2007-06-14
AU2006323992B2 true AU2006323992B2 (en) 2010-07-08

Family

ID=37831665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006323992A Ceased AU2006323992B2 (en) 2005-12-06 2006-12-05 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis

Country Status (13)

Country Link
US (4) US20080318988A1 (enExample)
EP (2) EP1959957B1 (enExample)
JP (4) JP2009518358A (enExample)
KR (2) KR101498848B1 (enExample)
CN (1) CN101321532B (enExample)
AU (1) AU2006323992B2 (enExample)
BR (1) BRPI0619416A2 (enExample)
CA (1) CA2629132C (enExample)
ES (2) ES2549327T3 (enExample)
PL (1) PL1959957T3 (enExample)
PT (1) PT1959957E (enExample)
RU (1) RU2450814C2 (enExample)
WO (1) WO2007065898A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009158447A2 (en) * 2008-06-27 2009-12-30 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
KR20110053354A (ko) * 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BR112012009094A8 (pt) * 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JP7230817B2 (ja) 2017-10-03 2023-03-01 凸版印刷株式会社 超音波シール用アンビル及び超音波シール装置
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
WO2026035611A1 (en) * 2024-08-05 2026-02-12 Amo Pharma Ltd Methods of treating neurofibromatosis using farnesyl dibenzodiazepinones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit
WO2006079539A2 (en) * 2005-01-28 2006-08-03 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2005049032A1 (en) * 2003-11-18 2005-06-02 Novartis Ag Inhibitors of the mutant form of kit
WO2006079539A2 (en) * 2005-01-28 2006-08-03 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BADACHE A et al. Oncogene. 1998. 17(6): 795-800 *
WEISBERG E et al. Cancer Cell. February 2005. 7(2): 129-141 *

Also Published As

Publication number Publication date
BRPI0619416A2 (pt) 2011-10-04
CN101321532A (zh) 2008-12-10
US20140073660A1 (en) 2014-03-13
JP2017193553A (ja) 2017-10-26
KR20080077973A (ko) 2008-08-26
PT1959957E (pt) 2012-10-29
PL1959957T3 (pl) 2012-12-31
KR101498848B1 (ko) 2015-03-05
KR101413387B1 (ko) 2014-06-27
RU2450814C2 (ru) 2012-05-20
ES2391199T3 (es) 2012-11-22
EP2177222B1 (en) 2015-07-15
CA2629132C (en) 2014-05-27
EP1959957B1 (en) 2012-07-18
US20080318988A1 (en) 2008-12-25
EP1959957A1 (en) 2008-08-27
AU2006323992A1 (en) 2007-06-14
KR20140022431A (ko) 2014-02-24
CA2629132A1 (en) 2007-06-14
JP2015091818A (ja) 2015-05-14
EP2177222A1 (en) 2010-04-21
RU2008127264A (ru) 2010-01-20
WO2007065898A1 (en) 2007-06-14
ES2549327T3 (es) 2015-10-27
US20100234408A1 (en) 2010-09-16
JP2009518358A (ja) 2009-05-07
CN101321532B (zh) 2011-06-29
US8604045B2 (en) 2013-12-10
US20130123290A1 (en) 2013-05-16
JP2013107893A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
WO2005039586A1 (en) Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
RU2481840C2 (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
KR101376875B1 (ko) 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
JP5154408B2 (ja) 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired